Navigation Links
Sunesis Receives Approval for Listing on The NASDAQ Capital Market
Date:7/30/2009

ions to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including without limitation statements related to the effective date of transfer of Sunesis' common stock to The NASDAQ The Capital Market and Sunesis compliance with The NASDAQ Capital Markets' continued listing requirements. Words such as "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis fails to comply with the continued listing requirements of The NASDAQ Capital Market and that Sunesis may be subject to delisting proceedings in the future. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Investor Contact:                          Media Contact:
    Sunesis Pharmaceuticals, Inc.              Sunesis Pharmaceuticals, Inc.
    Eric Bjerkholt   
'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/s3s3t8/personalized ) ... report "Personalized Medicine - Scientific and Commercial ... The aim of personalized medicine or individualized ... the right patient and, in some cases, even ... according to his/her genotype. This report describes the ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. , ... viral vectors, nonviral vectors and cell therapy with ... method of drug delivery and various routes of ...
(Date:3/3/2015)... PHILADELPHIA , March 3, 2015 ... agencies with tools for implementing competency-based training to comply ... DirectCourse is offering a new crosswalk ... Services (HCBS) implement competency-based training for direct service workers ... Medicare & Medicaid Services (CMS) regulations. CMS ...
(Date:3/3/2015)... 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer ... focus on protecting the microbiome, announced today that Jeffrey ... the 27th Annual ROTH Conference being held on March 8-11, ... in Dana Point, CA. Mr. Riley ... 1:00 p.m. (Pacific Time). A live webcast of ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Milwaukee, Wis. - Rick Davidson jokes ... global is in your title, and your company operates in ... especially in jest. , ,Not that the good-humored Davidson, senior ... is prone to exaggeration. The Milwaukee-based employment services firm has ...
... ago, I had no idea that I would continue with it ... to share with other members of the Midwest life-science community information ... just overall awareness about life science in the Midwest. , ... I couldn't afford the kind of market research we used to ...
... Baird Venture Partners , the U.S. venture fund of ... presence in China by partnering with the Indian investment and ... as they establish a foothold in the Indian market. In ... Baird Venture Partners and director of Baird Private Equity Group, ...
Cached Biology Technology:CIO Leadership Series: Rick Davidson, Manpower 2CIO Leadership Series: Rick Davidson, Manpower 3CIO Leadership Series: Rick Davidson, Manpower 4CIO Leadership Series: Rick Davidson, Manpower 5A Midwest life-science odyssey comes full circle 2A Midwest life-science odyssey comes full circle 3A Midwest life-science odyssey comes full circle 4A Midwest life-science odyssey comes full circle 5A Midwest life-science odyssey comes full circle 6A Midwest life-science odyssey comes full circle 7A Midwest life-science odyssey comes full circle 8Visions: Carbone bullish on Wisconsin venture capital 2Visions: Carbone bullish on Wisconsin venture capital 3Visions: Carbone bullish on Wisconsin venture capital 4Visions: Carbone bullish on Wisconsin venture capital 5
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... , Technological advancements in medicine have allowed patients suffering ... to regain mobility and live relatively pain-free. But some ... the U.S. Food and Drug Administration (FDA) are not ... is tested to determine its safety and effectiveness. ...
... , Muscular dystrophy is caused by the largest human gene, ... Research conducted at the University of Missouri and described this ... of Sciences has identified significant sections of ... and families. , MU scientists Dongsheng Duan, PhD, and Yi ...
... German . Trees do not grow in ... into oases for deep-sea life - at least temporarily until ... researchers from Germany now showed how sunken wood can develop ... By using underwater robot technology, they confirmed their hypothesis that ...
Cached Biology News:A call to prevent unsafe high-risk medical devices from reaching the marketplace 2A call to prevent unsafe high-risk medical devices from reaching the marketplace 3Scientists discover 'needle in a haystack' for muscular dystrophy patients 2Scientists discover 'needle in a haystack' for muscular dystrophy patients 3Wood on the seafloor -- an oasis for deep-sea life 2
DNA fragmentation factor & Inhibitor of CAD...
Rabbit polyclonal to ErbB 2 ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Component in MasterPure™ Purification Kits...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: